Editorial on the relationship between suPAR and CKD, published in NEJM

Wed Oct 21 2020

“A suPAR Biomarker for Chronic Kidney Disease”, published in the New England Journal of Medicine

The worldwide epidemic of Chronic Kidney Disease constitutes a death sentence in regions of the world where renal-replacement therapies are not available. Since decreased renal function is only detected after substantial kidney injury has already occurred, there is an urgent need to identify new biomarkers that accurately determine the risk of impending chronic kidney disease while renal function is still well preserved and there is higher likelihood that medical interventions can slow or prevent progression.

Studies that show that intervention based on suPAR levels is beneficial could cement a relationship between suPAR and chronic kidney disease.

Read the editorial here.


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPARnostic POC+


Point-of-care finger prick

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates